Blood Pressure Breakthroughs: Why Mineralys Stock Skyrocketed!
Mineralys shares surged 86% after AstraZeneca announced positive Phase 3 results for its similar blood pressure drug, Baxdrostat. "The results seem slightly worse than Mineralys' Lorundrostat," according to Jefferies. This could lead to business deals for MLYS, which may be "best in class".